The Form 4 filing, an SEC report of insider stock activity, was filed on November 17, 2026. It lists November 16, 2026, as the transaction date for Ceribell director Josef Parvizi.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 25,000 |
| Price | $26.02 |
| Total Transaction Value | $650,500.00 |
| Insider | |
| Ticker Symbol | CBLL |
| Company | Ceribell, Inc. |
| Insider Name | Parvizi Josef |
| Insider Title | Director |
| Sector - Industry | Healthcare - Medical Devices |
| Holdings | |
| Total Shares Owned After Transaction | 882,911 |
| Position Size Change | 2.75% |
| Filing | |
| Filing Date | 2026-11-17 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a share sale, reported with transaction code S. Josef Parvizi sold CBLL shares in one transaction.
What was the average price of the transaction?
The reported average price was $26.02 per share for the 25,000 shares sold.
How did this transaction affect the insider's holdings?
Josef Parvizi sold 25,000 shares and reported owning 882,911 shares afterward. The sale amounted to 2.75% of the shares he held before the trade. He still reported owning shares after the sale.
What's the total transaction value?
The single sale had a reported total value of $650,500.00.
Are there any special circumstances around this transaction?
The available transaction details include a Rule 10b5-1 reference. These trading plans set instructions in advance. The details do not show whether the reference covers this specific sale or the filing as a whole. Footnote text was not available to confirm its scope.
The details also do not state when the plan was set up or its trading schedule. The reference alone does not establish that the plan met the rule's legal requirements or explain why the shares were sold.
For research purposes only; not investment advice.